Personalized Cannabinoid Formulations and Experiences
Legal Citation
Summary of the Inventive Concept
A next-generation system for tailoring cannabinoid formulations to individual genotypes, providing optimal experiences through real-time biometric feedback, wearable tracking, and virtual reality simulation.
Background and Problem Solved
The original patent's cannabinoid formulations, while innovative, have limitations in terms of personalization and adaptability. The new inventive concept addresses these limitations by integrating genotype analysis, real-time biometric feedback, and AI-driven formulation optimization to provide a truly personalized experience.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for personalized cannabinoid formulations, including a genotype analysis module, a formulation generation module, and a dispensing module. The system can also incorporate wearable devices for tracking physiological and psychological responses, and a virtual reality platform for simulating optimal cannabinoid experiences. The formulations themselves can feature novel ratios of CBD:THC:CBG, dynamically adjusted based on real-time biometric data.
Novelty and Inventive Step
The new claims introduce a paradigm shift in cannabinoid formulation technology by incorporating genotype analysis, real-time biometric feedback, and AI-driven optimization. These innovations enable a level of personalization and adaptability not possible with traditional formulations.
Alternative Embodiments and Variations
Alternative embodiments may include the use of machine learning algorithms to predict optimal formulations, integration with electronic health records, or the development of specialized formulations for specific medical conditions. Variations may include the use of different cannabinoids, terpenes, or other compounds to create unique formulations.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the burgeoning cannabis industry, particularly in the areas of personalized medicine, wellness, and recreational use. Target industries may include pharmaceuticals, nutraceuticals, and cannabis dispensaries.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically cannabinoid formulation design with a focus on personalized medicine and genetic variation analysis
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, biotechnology, or pharmacogenomics, possessing expertise in cannabinoid chemistry, genetic analysis, and personalized drug formulation techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's personalized cannabinoid formulation system represents a predictable extension of the source patent's foundational work in genotype-aligned cannabinoid compositions. The core innovation of tailoring cannabinoid ratios based on genetic polymorphisms was already established in the source patent, making the PTD's additional technological implementations a logical progression. The integration of biometric tracking, virtual reality simulation, and dynamic formulation adjustment would be considered obvious improvements using known techniques in personalized medicine and biotechnology.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,530 |
|---|---|
| Title | Cannabinoid formulations |
| Assignee(s) | Endocanna Health, Inc. |